This is a summary of the European public assessment report (EPAR) for Elmiron. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Elmiron. For practical information about using Elmiron, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Elmiron is indicated for the treatment of bladder pain syndrome characterized by either glomerulations or Hunner’s lesions in adults with moderate to severe pain, urgency and frequency of micturition.
Therapeutic Area (MeSH)
N/AATC Code
G04BX15
ATC Item
pentosan polysulfate sodium
Pharmacotherapeutic Group
Urologicals
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| pentosan polysulfate sodium | N/A | pentosan polysulfate sodium |
EMA Name
Elmiron
Medicine Name
Elmiron
Aliases
N/ANo risk management plan link.
